Literature DB >> 17212704

PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.

J Sun1, K Xu, C Wu, Y Wang, Y Hu, Y Zhu, Y Chen, Q Shi, G Yu, X Zhang.   

Abstract

Programmed death-1 ligand-1 (PD-L1), a member of the B7 family of costimulatory molecules, plays an important role in the regulations of the cellular and humoral immune responses. In this study, two mouse anti-human PD-L1 monoclonal antibodies named 10E10 and 2H11 were successfully generated and further characterized. Monoclonal antibody 10E10 bound to distinct PD-L1 epitope comparing an available anti-PD-L1 monoclonal antibody on a series of malignant cell lines, activated T lymphocytes, B lymphocytes and dendritic cells. Then, by using immunohistochemistry staining with monoclonal antibody 2H11, the expression of PD-L1 was found in human gastric carcinoma specimens but not in normal or gastric adenoma tissues. Additional data show that PD-L1 can be regarded as a decisive factor in evaluating gastric carcinoma prognosis and anti-human PD-L1 monoclonal antibody 10E10 could inhibit T-cell apoptosis induced by tumor-associated PD-L1. Taken together, these results showed that the two functional mouse anti-human PD-L1 monoclonal antibodies we generated might be of great value for further exploration of the costimulatory molecule regulating network and immunointervention for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17212704     DOI: 10.1111/j.1399-0039.2006.00701.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  37 in total

1.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

Authors:  Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu
Journal:  Oncoimmunology       Date:  2016-11-22       Impact factor: 8.110

Review 3.  Immunotherapy in upper GI malignancies.

Authors:  Adrian Murphy; Ronan J Kelly
Journal:  Curr Treat Options Oncol       Date:  2015-05

Review 4.  Targeted therapies in gastric cancer treatment: where we are and where we are going.

Authors:  Gianluca Tomasello; Michele Ghidini; Wanda Liguigli; Margherita Ratti; Laura Toppo; Rodolfo Passalacqua
Journal:  Invest New Drugs       Date:  2016-02-12       Impact factor: 3.850

5.  Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.

Authors:  Shan-Shan Zhang; Jing Tang; Shu-Yi Yu; L I Ma; Feng Wang; Shu-LE Xie; Long Jin; Hong-Yu Yang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

6.  T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.

Authors:  Binfeng Lu; Lujun Chen; Lin Liu; Yibei Zhu; Changping Wu; Jingting Jiang; Xueguang Zhang
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

7.  Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.

Authors:  Jin Won Kim; Kyung Han Nam; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim; Se Hyun Kim; Hyun Chang; Jeong-Ok Lee; Yu Jung Kim; Hye Seung Lee; Jee Hyun Kim; Soo-Mee Bang; Jong Seok Lee; Keun-Wook Lee
Journal:  Gastric Cancer       Date:  2014-11-26       Impact factor: 7.370

8.  An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.

Authors:  Jiyoon Bu; Ashita Nair; Mari Iida; Woo-Jin Jeong; Michael J Poellmann; Kara Mudd; Luke J Kubiatowicz; Elizabeth W Liu; Deric L Wheeler; Seungpyo Hong
Journal:  Nano Lett       Date:  2020-06-11       Impact factor: 11.189

Review 9.  Gastric cancer: The times they are a-changin'.

Authors:  Maria Antonietta Satolli; Lucio Buffoni; Rosella Spadi; Ilaria Roato
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

Review 10.  Personalized medicine in gastric cancer: Where are we and where are we going?

Authors:  Alexandre A Jácome; Anelisa K Coutinho; Enaldo M Lima; Aline C Andrade; José Sebastião Dos Santos
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.